Related Experiment Video

Updated: Jul 12, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

Real-world clinical experience with weekly somatrogon in pediatric growth hormone deficiency: A French longitudinal

Isabelle Flechtner1, Catherine Brue1, Frédérique Gastaud1

  • 1Association Française des Pédiatres Endocrinologues Libéraux (AFPEL), 150, rue de Charenton, 72012 Paris, France.

Annales D'Endocrinologie
|July 10, 2026
PubMed

Insights

Weekly somatrogon showed effectiveness in pediatric growth hormone deficiency (GHD) patients, but caused rapid BMI increase and higher discontinuation rates in those switching from daily growth hormone (dGH). Careful monitoring and education are recommended.

Area of Science:

  • Pediatric Endocrinology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Growth hormone deficiency (GHD) impacts pediatric growth and development.
  • Current treatments for GHD include daily growth hormone (dGH) injections.
  • Weekly somatrogon offers a potential alternative for GHD management.

Purpose of the Study:

  • To evaluate the real-world effectiveness, safety, and metabolic impact of weekly somatrogon in pediatric GHD patients.
  • To compare outcomes between treatment-naive patients and those switching from dGH.
  • To identify factors influencing treatment response and adverse events.

Main Methods:

  • Retrospective and prospective observational cohort study with up to 24 months follow-up.
  • 163 pediatric patients with GHD included: 92 treatment-naive, 71 switched from dGH.
  • Monitored growth parameters, BMI z-scores, IGF1 levels, and adverse events; used multivariate regression for BMI predictors.

Main Results:

  • Height gain was 10.0 cm/year in naive and 7.0 cm/year in switch patients.
  • Significant biphasic BMI z-score increase (+0.81 SD) observed, stabilizing after 14 months.
  • 15% discontinuation rate, higher in switch group (22.5%), mainly due to injection site pain and weight gain; lipoatrophy in 15 patients.

Conclusions:

  • Somatrogon demonstrated comparable growth to dGH but led to rapid BMI catch-up and higher discontinuation in switch patients.
  • Prioritize nutritional monitoring and injection site rotation education to mitigate BMI increase and local adverse effects.
  • Further longitudinal studies are needed to assess metabolic changes and body composition accurately.
Abstract

Keywords:
Body mass indexGrowth hormone deficiencyLipoatrophyLong acting growth hormonePainSomatrogon

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...